Overview

  • Product nameAnti-p53 (phospho S15) antibody
    See all p53 primary antibodies
  • Description
    Rabbit polyclonal to p53 (phospho S15)
  • SpecificityThe Phospho-p53 (Ser15) antibody detects ~53 kDa Ser15 phosphorylated p53. It does not react with non-phosphorylated p53 or p53 phosphorylated at other sites.
  • Tested applicationsSuitable for: IHC-Fr, ICC/IF, IHC-P, WB, IPmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human p53 (intracellular). Synthetic phospho-peptide surrounding amino acid Ser15 of human p53
    Database link: P04637

  • Positive control
    • Rat Bone Marrow Cells, UV treated HeLa Cells

Properties

Applications

Our Abpromise guarantee covers the use of ab1431 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration.
IHC-P Use a concentration of 20 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. PubMed: 23365256
WB Use a concentration of 0.5 - 4 µg/ml. Predicted molecular weight: 53 kDa.
IP Use a concentration of 5 - 10 µg/ml.

Target

  • FunctionActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
  • Tissue specificityUbiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
  • Involvement in diseaseNote=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.
    Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].
    Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers.
    Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
    Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980].
    Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood.
    Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.
  • Sequence similaritiesBelongs to the p53 family.
  • DomainThe nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.
  • Post-translational
    modifications
    Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.
    Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.
    Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
    May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
    Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.
    Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation.
    Sumoylated by SUMO1.
  • Cellular localizationCytoplasm; Cytoplasm. Nucleus. Nucleus > PML body. Endoplasmic reticulum. Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2; Nucleus. Cytoplasm. Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli; Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells; Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm; Nucleus. Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4 and Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cytoplasm following cell stress.
  • Information by UniProt
  • Database links
  • Alternative names
    • Antigen NY-CO-13 antibody
    • BCC7 antibody
    • Cellular tumor antigen p53 antibody
    • FLJ92943 antibody
    • LFS1 antibody
    • Mutant tumor protein 53 antibody
    • p53 antibody
    • p53 tumor suppressor antibody
    • P53_HUMAN antibody
    • Phosphoprotein p53 antibody
    • Tp53 antibody
    • Transformation related protein 53 antibody
    • TRP53 antibody
    • Tumor protein 53 antibody
    • Tumor protein p53 antibody
    • Tumor suppressor p53 antibody
    see all

Anti-p53 (phospho S15) antibody images



  • Predicted band size : 53 kDa
    Lane 1 = Extract of Hek293T cells incubated with vehicle ? 20 ug. Lane 2 = Extract of Hek293T cells incubated with etoposide ? 20 ug. Lane 3 = Extract of Mcf7 cells incubated with vehicle ? 20 ug. Lane 4 = Extract of Mcf7 cells incubated 6 hours with camptothecin ? 20 ug.
    Lane 5 = Extract of Mcf7 cells incubated 16 hours with camptothecin ? 20 ug. Lane 6 = Extract of Mcf7 cells incubated 24 hours with camptothecin ? 20 ug. Lane 7 = Extract of Hek293T incubated with etoposide ? 7.5 ug. Lane 8 = Lambda phosphatase (400 times-diluted)-treated extract of Hek293T incubated with etoposide -7.5 ug. Lane 9 = Lambda phosphatase (100 times-diluted)-treated extract of Hek293T incubated with etoposide -7.5 ug. Lane 10 = Lambda phosphatase (25 times-diluted)-treated extract of Hek293T incubated with etoposide -7.5 ug.
    SDS PAGE performed under reducing conditions (100mM DTT ? Sample heated at 50?C). Primary : Lanes 1-10: Anti p53 (phospho S15) antibody (ab1431) at 1 ug/mL. Secondary : Lanes 1-10: Goat anti rabbit IgG(H&L)-HRP at 1:10000. Developed: ECL with 2 min exposure.
    Blocking: in 5% Milk + PBS for 3 hours at RT. Primary antibody: in 5% BSA + PBS overnight at 4 C. Secondary antibody: in 5% Milk + PBS for 2 hour at RT. Predicted band size : 53kDa. Observed band size : 53kDa.
  • ab1431 staining p53 in Mouse bone marrow WBCs cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with formaldehyde, permeabilized with 0.1% Triton X-100 and blocked with 5% serum for 2 hours at 25°C. Samples were incubated with primary antibody (1/100 in PBS) for 12 hours at 4°C. An Alexa Fluor® 488-conjugated Goat anti-rabbit IgG polyclonal (1/500) was used as the secondary antibody.

    See Abreview

  • All lanes : Anti-p53 (phospho S15) antibody (ab1431)

    Lane 1 : HeLa whole cell lysate (ab150035)
    Lane 2 : HeLa DNA Damage Whole Cell Lysate Set: UV Treated and Untreated Control (ab157396)


    Predicted band size : 53 kDa
    Western blot analysis of extract from untreated (lane 1) and UV treated (lane 2) HeLa cells.
  • ab1431 staining p53 in rat bone marrow cells by Immunocytochemistry/ Immunofluorescence. The cells were paraformaldehyde fixed, permeabilised in 0.1% Triton X-100 and then blocked using 5% BSA for 1 hour at 25°C. Samples were then incubated with primary antibody at 1:100 for 9 hours at 4°C. The secondary antibody used was a goat anti-rabbit Alexa Fluor® 488 (green) ab150077) used at a 1/250 dilution. DAPI was used to stain the cell nuclei (blue).These pictures were taken in the different fields of the same bone marrow cell slide.

    See Abreview

References for Anti-p53 (phospho S15) antibody (ab1431)

This product has been referenced in:
  • Tan S  et al. Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancer. Oncol Lett 9:2056-2062 (2015). WB ; Mouse . Read more (PubMed: 26137012) »
  • Polettini J  et al. Telomere Fragment Induced Amnion Cell Senescence: A Contributor to Parturition? PLoS One 10:e0137188 (2015). WB ; Human . Read more (PubMed: 26397719) »

See all 16 Publications for this product

Product Wall

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa)
Permeabilization Yes - 0.5% TritonX100 in PBS
Specification HeLa
Fixative Paraformaldehyde
Username

Dr. Kirk McManus

Verified customer

Submitted Aug 12 2016

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Frozen sections)
Sample Mouse Tissue sections (fetal lung)
Specification fetal lung
Fixative Paraformaldehyde
Permeabilization Yes - PBST for 1 hour
Blocking step Serum as blocking agent for 20 minute(s) · Concentration: 1.5% · Temperature: 4°C
Username

Abcam user community

Verified customer

Submitted Apr 16 2013

Thank you for your participation in Abcam's post complaint survey.

I am glad to hear that your satisfied with our service. Although the outcome of a working antibody is always prefered,unfortunately, we needed to refund you purchase as the fr...

Read More

Thank you for contacting us.

Our p53 antibody ab26 has been optimized by loading 20 ug per lane of HeLa cells, using 5% BSA as the blocking agent for 1 hour at room temperature, and incubating with the primary antibody at a concentration of 5...

Read More

Thank you for contacting us.

Your credit note ID is xxx.

I am sorry that this antibody did not perform as stated on the datasheet. If payment has already been made on the original order and you wish to receive a refund, please ask...

Read More

Thank you for contacting Abcam. Attached please find the certificate of compliance you requested. I hope this information is helpful.  Please do not hesitate to contact us if you have any additional questions.

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Mouse Cell (bone marrow WBCs)
Specification bone marrow WBCs
Fixative Formaldehyde
Permeabilization Yes - 0.1% Triton X-100
Blocking step Serum as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Feb 18 2011

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (HCT116p53wt cells)
Loading amount 30 µg
Specification HCT116p53wt cells
Treatment irradiated (10Gy)
Gel Running Conditions Reduced Denaturing (10% Tris-Gly gel)
Blocking step LI-COR® Odyssey® Blocking Buffer as blocking agent for 45 minute(s) · Concentration: 50% · Temperature: RT°C
Username

Dr. Svetlana Khoronenkova

Verified customer

Submitted Oct 29 2010

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Rat Cell (Bone marrow cell)
Specification Bone marrow cell
Fixative Paraformaldehyde
Permeabilization Yes - 0.1% Triton X-100
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted May 10 2010

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (HEK 293 and RWPE-1 prostate epithelial)
Loading amount 20 µg
Specification HEK 293 and RWPE-1 prostate epithelial
Treatment UV 10 and 50 uM etoposide for 4 hrs
Gel Running Conditions Reduced Denaturing (4-20%)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 2% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Nov 05 2009

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"